DANVILLE, Pa., May 10, 2024 /PRNewswire/ — Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. The team is also the first to in the U.S. to screen for the trial. “If a patient qualifies for the…
Tag: Geisinger
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids […]
Geisinger researchers find AI can predict death risk
Algorithm using echocardiogram videos of the heart outperforms other predictors of mortality DANVILLE, Pa., Feb. 9, 2021 /PRNewswire/ — Researchers at Geisinger have found that a computer algorithm developed using echocardiogram videos of the heart can predict mortality within a year. The algorithm—an […]
National Institutes of Health awards Geisinger over $3.1 million for research of sudden cardiac death
DANVILLE, Pa., March 4, 2019 /PRNewswire/ — The National Institutes of Health has awarded researchers at Geisinger $3.1 million over the next five years to explore innovative approaches for early, genomics-based detection of arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is a degenerative heart disease responsible […]